Genetic mechanisms underlying Duchenne muscular dystrophy point to potential treatments
Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...
pharmaphorum21h
Santhera's DMD drug poised for wider rollout in Germany
The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...
Managed Healthcare Executive1d
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Hosted on MSN2d
Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247
Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...
Pharmabiz1h
Santhera announces agreement with German GKV-SV on reimbursement for Agamree to treat Duchenne muscular dystrophy
Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...
The American Journal of Managed Care7d
Duchenne Muscular Dystrophy
An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies. Septal ...
The American Journal of Managed Care6d
Ifetroban Improves Heart Function in DMD
There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...
Managed Healthcare Executive1d
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
The Independent1d
Massillon community unites to gather Valentine's Day cards for 7-year-old Vinny DeMando
An effort is ongoing to collect valentines for Massillon resident Vinny DeMando, 7, who has muscular dystrophy. Cards are ...